Charles Theuer - 12 Mar 2024 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.

Role: PRESIDENT AND CEO, Director
Signature: /s/ Scott B. Brown, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 12 Mar 2024
Net transactions value: +$948
Form type: 4
Filing time: 13 Mar 2024, 17:56:13 UTC
Previous filing: 30 Jun 2023
Next filing: 23 May 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCON	Common Stock	Award	$482	+3,500	+0.88%	$0.1377	402,917	20 Apr 2023	Direct	F1
transaction	TCON	Common Stock	Award	$467	+3,500	+0.87%	$0.1333	406,417	20 Oct 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TCON	Employee Stock Option (Right to Buy)	Award	$0	+518,300		$0.000000	518,300	12 Mar 2024	Common Stock	518,300	$0.3900	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on April 20, 2023.
F2	Shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on October 20, 2023.
F3	1/4th of the shares subject to this option shall vest on the first anniversary of the Grant Date shown in column 3 above. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter, on the last day of each month.